Glaxo Wins U.S. Ruling on Migraine Drug

By Bloomberg Business News

Published: June 3, 1995

LONDON, June 2—
Glaxo Wellcome P.L.C. said today that the Food and Drug Administration in the United States had decided that the company could begin selling a tablet version of its prescription migraine treatment Imitrex.

The decision, which Glaxo requested more than four years ago, is expected to bolster sales of what is one of Glaxo's fastest-growing products, but one that has been dogged by safety concerns.

Imitrex was previously approved only in injectable form in the United States, its largest market. On April 3, Glaxo said the F.D.A. had agreed to approve the drug in tablet form, which usually means final approval will follow shortly.

The drug, chemically known as sumatriptan, is one of a few new treatments in a market largely unserved by new medications.